The Bioassay Advantage
The use of Mechanism of Action (MoA)-based bioassays to measure the activity of Antibody-based therapeutic drug candidates is critical throughout the drug development workflow. Promega bioassays offer a rapid and simple workflow compared to traditional methods that rely on inconsistent methods involving primary cell culture to measure potency of biologics.
Promega Bioassay General Principle. Bioassay Effector Cells are engineered to express either FcγR, or immune checkpoint or cytokine or growth factor receptors/ligands and luciferase reporters driven by an appropriate response element that is based on MoA. In the presence of antibody and/or target cells expressing the relevant antigen, the effector cells will transduce intracellular signals, resulting in luciferase activity that can be easily quantified.
Bioassays for Academic Research
Fc Effector Reporter Bioassays
Reporter bioassays to measure the potency and stability of antibodies and other biologics that specifically bind and activate Fcγ receptors.
- Human ADCC Reporter Bioassays
- Human ADCP Reporter Bioassays
- Mouse ADCC Reporter Bioassay
PBMC Primary Cell Bioassays
ADCC qualified human PBMCs along with engineered Target cells expressing HiBiT protein to measure the potency and stability of antibodies and other biologics that specifically bind and activate Fcγ receptors.
- PBMC ADCC Bioassay Kit – Raji, Ramos, A549, SK-BR-3, H929 Targets
T Cell Redirecting/Activation Bioassays
T Reporter bioassays to accelerate the discovery and development of novel biologics, such as bispecific antibodies, TCR therapy and CAR-T cell therapies.
- T Cell Activation Bioassay (NFAT)
- T Cell Activation Bioassay (IL-2)
- CD8+ TCRαβ-KO T Cell Bioassay
- CD4+ TCRαβ-KO T Cell Bioassay
- CD4+/CD8+ TCRαβ-KO T Cell Bioassay
Immune Checkpoint Modulation Bioassays
Reporter bioassays to measure the potency and stability of antibodies and other biologics designed to block the interaction between immune checkpoint receptors and their ligands.
- Co-inhibitory Receptor Bioassays for PD-1, CTLA-4, TIGIT, TIM-3, VISTA, HVEM, LAG-3
- Co-stimulatory Receptor Bioassays for GITR, OX40, CD40, 4-1BB, CD27, CD28 and ICOS
- Combination bioassays for PD-1+TIGIT, PD-1+CTLA-4, PD-1+LAG-3, PD-1+4-1BB
Cytokine and Growth Factor Modulation Bioassays
Reporter bioassays to quantify and monitor the activity of ligands, as well as antibody-mediated blockade of ligand receptor binding.
- VEGF, RANKL, TNFα, TGFβ, IFNα, IFNβ and IFNγ
- IL-2, IL-6, IL-12, IL-15, IL-17 and IL-23
Learn more about Promega bioassays for biologics
CRISPR-Engineered Cell Lines
By using CRISPR/Cas9 gene editing to knock in a tag at endogenous loci of interest, proteins expressed by the native promoter can be studied using simple optical output measurements. Compared to overexpression models, endogenously tagged proteins maintain natural epigenetic regulation and stoichiometry with native interacting partners, resulting in improved assay windows, minimized artifacts, and more accurate models of protein biology under physiologically relevant conditions.
HiBiT Protein Tagging System
HiBiT simplifies protein detection, providing a streamlined, antibody-free protocol for detecting tagged proteins.
The small size (19KDa) and bright luminescence of NanoLuc® Luciferase brings exquisite sensitivity to many applications, including studying genetic responses and protein dynamics in cells at physiologically relevant levels.
Investigate protein function by adding the HaloTag® to your protein, paired with one of many interchangeable ligands that forms a highly specific covalent bond with HaloTag.
Still Have Questions?
Read through the answers to the frequently asked questions.
What products are included in the program? Promega’s full portfolio of functional bioassays and pre-built CRISPR-edited cell lines are included in the AAP.
Can I include other products? The aim of the AAP is to increase collaboration between academic researchers and Promega. Should you require something outside the scope of the current AAP, please contact your local Promega account manager to discuss your requirements.
What about CRISPR content? Promega is fully licensed to produce and provide CRISPR engineered cell lines to all customer segments. AAP specific pricing applies to these cell lines.
What pricing will I be offered? Pricing depends on the type of engagement and collaboration you agree upon with your Promega account manager.
Are there minimum order requirements? There are no requirements for order size, volume or frequency.
Is there a fee to join? Aside from the cost of the products you purchase, there is no additional cost to join the program.
What’s the catch? There is no catch, but there are terms and conditions. The terms and conditions are designed to support a partnership between Promega and academic researchers to apply Promega’s cutting edge technologies to the most urgent biomedical research needs at an affordable academic price. Terms and conditions are specific to each geographical region and you should contact your local Promega account manager for more information.
What do you expect from me? The Promega Academic Access Program is a tool to enable research and the level of commitment and collaboration will depend upon the research activity. We may require you to share product related data with our R&D team (in complete confidence) or we may offer you the opportunity to present your work at a conference attended by Promega. The exact level of collaboration will be agreed upon prior to acceptance into the AAP.
What is an innovator network? An innovator network is a group of like-minded researchers who are pursuing the same research goal or are using the same types of Promega products. We wish to connect people who are doing the same type of research to enhance discussion and accelerate discovery. We are committed to moving science forward and developing additional tools and technologies identified by the innovator network as relevant to their research. Promega will support the creation of innovator networks either virtually (among organizations) or physically (within organizations).
What opportunities are there to present my work? Participants within the AAP may be offered the opportunity to present a poster or talk at a meeting or conference. These meetings can occur in any part of the world and registration and travel costs will be sponsored by Promega. Other opportunities to share research could involve participating in a webinar or coauthoring papers or application notes.
Who can join? If you are working in immuno-oncology, inflammatory response, vaccine development or other areas where next-generation biologic drugs are being discovered, then we would like to hear from you. Our goal is to collaborate with key thought leaders in these disciplines within the academic environment to accelerate research and development globally.
What are the benefits to joining?
- Early access to development project material pertaining to your area of research.
- Direct access to Promega R&D and ATG (Advanced Technology Group) scientists, along with the possibility to influence the direction of Promega product development activities.
- Opportunity to join or create an Innovator Network of experts in your field of research supported by Promega.
Join the Academic Access Program
To learn more and find out if you qualify for the program, fill out this form to tell us about you and your research.